Christophe Weber [Getty Images]

Take­da preps an­oth­er drug auc­tion as ex­ecs look to fur­ther trim its post-Shire buy­out debt load — re­port

Take­da is pol­ish­ing up an­oth­er piece of the drug port­fo­lio for auc­tion as it looks to whit­tle down the big debt it took on to buy Shire.

Af­ter sell­ing off Xi­idra to No­var­tis for $5.3 bil­lion, Reuters now re­ports Take­da has a slate of OTC and pre­scrip­tion drugs in Eu­rope it’s pack­aged to­geth­er and priced at a hope­ful $1.7 bil­lion. Earn­ings ahead of EBIT­DA are 160 mil­lion eu­ros a year, so the range is just over 10X.

Endpoints News

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.